Please wait a minute...
浙江大学学报（医学版）
浙江大学学报（医学版）  2021, Vol. 50 Issue (5): 659-665    DOI: 10.3724/zdxbyxb-2021-0170
综述     
磷酸二酯酶抑制剂治疗炎性肠病的研究进展
史建蓉1,马望前2,汤慧芳3,*()
1.浙江大学医学院附属儿童医院实验检验中心 国家儿童健康与疾病临床医学研究中心 国家儿童区域医疗中心，浙江 杭州 310052
2.浙江大学医学院附属第二医院消化内科，浙江 杭州 310009
3.浙江大学基础医学院药理学系，浙江 杭州 310058
Research progress of phosphodiesterase inhibitors in inflammatory bowel disease treatment
SHI Jianrong1,MA Wangqian2,TANG Huifang3,*()
1. Clinical Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children’s Regional Medical Center, Hangzhou 310052, China;
2. Department of Gastroenterology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China;
3. Department of Pharmacology, School of Basic Medical Sciences, Zhejiang University, Hangzhou 310058, China
 全文: PDF(2041 KB)   HTML( 14 )
摘要：

炎性肠病是一种慢性复发性肠道炎性疾病，尚无理想治疗方法。磷酸二酯酶（PDE）通过介导细胞内第二信使环磷酸腺苷和环磷酸鸟苷的水解影响细胞内信号级联反应，从而调控多种病理、生理过程。近年来，一系列研究结果显示，PDE抑制剂如多种PDE4抑制剂、PDE5抑制剂（西地那非、他达拉非及伐地那非）、PDE3抑制剂（西洛他唑）、PDE9抑制剂（PF-04447943）、PDE3/PDE4双抑制剂（pumafentrine）对实验性结肠炎具有改善作用；PDE4抑制剂阿普司特在临床试验中较替托司特的治疗优势更明显。本文就PDE抑制剂在炎性肠病治疗中的研究进展进行综述。
关键词： 炎性肠病;  磷酸二酯酶;  磷酸二酯酶抑制剂;  环磷酸腺苷;  环磷酸鸟苷;  综述    
Abstract:

Inflammatory bowel disease is a recurrent chronic intestinal inflammatory disease with unknown etiology and no effective treatment. Phosphodiesterase (PDE) regulates a variety of physiological and pathophysiological processes by mediating the hydrolysis of intracellular second messengers cyclic adenosine monophosphate and cyclic guanosine monophosphate. In recent years, a series of researches suggest that PDE inhibitors such as several PDE4 inhibitors, PDE5 inhibitors (sildenafil, tadalafil and vardenafil), PDE3 inhibitors (cilostazol), PDE9 inhibitor (PF-04447943) and PDE3/PDE4 double inhibitor (pumafentrine) have ameliorating effect on experimental colitis in animals. In clinical trials, PDE4 inhibitor apremilast showed more therapeutic advantage than tetomilast. This article reviews the recent research progress of PDE inhibitors in treatment of inflammatory bowel disease.
Key words: Inflammatory bowel disease    Phosphodiesterase    Phosphodiesterase inhibitor    Cyclic adenosine monophosphate    Cyclic guanosine monophosphate    Review
收稿日期: 2021-06-18 出版日期: 2021-12-29
:  R967  
基金资助: 国家自然科学基金（81402989）； 浙江省基础公益研究计划（LGD20H010002）
通讯作者: 汤慧芳     E-mail: tanghuifang@zju.edu.cn
服务　　
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章　　
史建蓉
马望前
汤慧芳

引用本文:

史建蓉,马望前,汤慧芳. 磷酸二酯酶抑制剂治疗炎性肠病的研究进展[J]. 浙江大学学报（医学版）, 2021, 50(5): 659-665.

SHI Jianrong,MA Wangqian,TANG Huifang. Research progress of phosphodiesterase inhibitors in inflammatory bowel disease treatment. J Zhejiang Univ (Med Sci), 2021, 50(5): 659-665.

链接本文:

https://www.zjujournals.com/med/CN/10.3724/zdxbyxb-2021-0170    或    https://www.zjujournals.com/med/CN/Y2021/V50/I5/659

1 BERNSTEINC N. Review article: changes in the epidemiology of inflammatory bowel disease-clues for aetiology[J]Aliment Pharmacol Ther, 2017, 46( 10): 911-919.
doi: 10.1111/apt.14338
2 NGS C, SHIH Y, HAMIDIN, et al.Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies[J]Lancet, 2017, 390( 10114): 2769-2778.
doi: 10.1016/S0140-6736(17)32448-0
3 BOURGONJEA R, FEELISCHM, FABERK N, et al.Oxidative stress and redox-modulating therapeutics in inflammatory bowel disease[J]Trends Mol Med, 2020, 26( 11): 1034-1046.
doi: 10.1016/j.molmed.2020.06.006
4 TIANT, WANGZ, ZHANGJ. Pathomechanisms of oxidative stress in inflammatory bowel disease and potential antioxidant therapies[J]Oxid Med Cell Longev, 2017, 1-18.
doi: 10.1155/2017/4535194
5 RUBIND T, ANANTHAKRISHNANA N, SIEGELC A, et al.ACG clinical guideline: ulcerative colitis in adults[J]Am J Gastroenterol, 2019, 114( 3): 384-413.
doi: 10.14309/ajg.0000000000000152
6 HINDRYCKXP, NOVAKG, COSTANZOA, et al.Disease-related and drug-induced skin manifestations in inflammatory bowel disease[J]Expert Rev Gastroenterol Hepatol, 2017, 11( 3): 203-214.
doi: 10.1080/17474124.2017.1283985
7 TRIPATHIK, FEUERSTEINJ D. New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance[J]Drugs Context, 2019, 212572.
doi: 10.7573/dic.212572
8 AHMADF, MURATAT, SHIMIZUK, et al.Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets[J]Oral Dis, 2015, 21( 1): 25-50.
doi: 10.1111/odi.12275
9 SALARIP, ABDOLLAHIM. Phosphodiesterase inhibitors in inflammatory bowel disease[J]Expert Opin Investig Drugs, 2012, 21( 3): 261-264.
doi: 10.1517/13543784.2012.658915
10 MOKRAD, MOKRYJ. Phosphodiesterase inhibitors in acute lung injury: what are the perspectives?[J]Int J Mol Sci, 2021, 22( 4): 1929.
doi: 10.3390/ijms22041929
11 GIORGIM, CARDARELLIS, RAGUSAF, et al.Phosphodiesterase inhibitors: could they be beneficial for the treatment of COVID-19?[J]Int J Mol Sci, 2020, 21( 15): 5338.
doi: 10.3390/ijms21155338
12 YASMEENS, AKRAMB H, HAINSWORTHA H, et al.Cyclic nucleotide phosphodiesterases (PDEs) and endothelial function in ischaemic stroke. A review[J]Cell Signal, 2019, 108-119.
doi: 10.1016/j.cellsig.2019.05.011
13 SCHEPERSM, TIANEA, PAESD, et al.Targeting phosphodiesterases—towards a tailor-made approach in multiple sclerosis treatment[J]Front Immunol, 2019, 1727.
doi: 10.3389/fimmu.2019.01727
14 WAHLANGB, MCCLAINC, BARVES, et al.Role of cAMP and phosphodiesterase signaling in liver health and disease[J]Cell Signal, 2018, 105-115.
doi: 10.1016/j.cellsig.2018.06.005
15 PENGT, GONGJ, JINY, et al.Inhibitors of phosphodiesterase as cancer therapeutics[J]Eur J Medicinal Chem, 2018, 742-756.
doi: 10.1016/j.ejmech.2018.03.046
16 KNOTTE P, ASSIM, RAOS N R, et al.Phosphodiesterase inhibitors as a therapeutic approach to neuroprotection and repair[J]Int J Mol Sci, 2017, 18( 4): 696.
doi: 10.3390/ijms18040696
17 SCHMIDTC, GRUNERTP C, STALLMACHA. An update for pharmacologists on new treatment options for inflammatory bowel disease: the clinicians’ perspective[J]Front Pharmacol, 2021, 655054.
doi: 10.3389/fphar.2021.655054
18 LIH, FANC, FENGC, et al.Inhibition of phosphodiesterase‐4 attenuates murine ulcerative colitis through interference with mucosal immunity[J]Br J Pharmacol, 2019, 176( 7): bph.14667.
doi: 10.1111/bph.14667
19 LIH, ZUOJ, TANGW. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases[J]Front Pharmacol, 2018, 1048.
doi: 10.3389/fphar.2018.01048
20 薛恩复, 马望前, 汤慧芳. 磷酸二酯酶4抑制剂治疗炎症性肠病研究进展[J]. 中国药理学与毒理学杂志, 2019, 33(7): 535-541
XUE Enfu, MA Wangqian, TANG Huifang. Research progress in phosphodiesterase 4 inhibitors in treatment of inflammatory bowel diseases[J]. Chinese Journal of Pharmacology and Toxicology, 2019, 33(7): 535-541. (in Chinese)
21 KESHAVARZIANA, MUTLUE, GUZMANJ P, et al.Phosphodiesterase 4 inhibitors and inflammatory bowel disease: emerging therapies in inflammatory bowel disease[J]Expert Opin Investig Drugs, 2007, 16( 9): 1489-1506.
doi: 10.1517/13543784.16.9.1489
22 SCHREIBERS, KESHAVARZIANA, ISAACSK L, et al.A randomized, placebo-controlled, phase Ⅱ study of tetomilast in active ulcerative colitis[J]Gastroenterology, 2007, 132( 1): 76-86.
doi: 10.1053/j.gastro.2006.11.029
23 DANESE S, NEURATH M, KOPON A, et al. Apremilast for active ulcerative colitis: a phase 2, randomised, double-blind, placebo-controlled induction study[J]. Gastroenterology, 2018, 154(6): s-167
24 DANESES, NEURATHM F, KOPO?A, et al.Effects of apremilast, an oral inhibitor of phosphodiesterase 4, in a randomized trial of patients with active ulcerative colitis[J/OL]Clin Gastroenterol Hepatol, 2020, 18( 11): 2526-2534.e9.
doi: 10.1016/j.cgh.2019.12.032
25 MISSELWITZB, JUILLERATP, SULZM C, et al.Emerging treatment options in inflammatory bowel disease: Janus kinases, stem cells, and more[J]Digestion, 2020, 101( Suppl. 1): 69-82.
doi: 10.1159/000507782
26 SPADACCINIM, D’ALESSIOS, PEYRIN-BIROU-LETL, et al.PDE4 inhibition and inflammatory bowel disease: a novel therapeutic avenue[J]Int J Mol Sci, 2017, 18( 6): 1276.
doi: 10.3390/ijms18061276
27 AHMADF, DEGERMANE, MANGANIELLOV C. Cyclic nucleotide phosphodiesterase 3 signaling complexes[J]Horm Metab Res, 2012, 44( 10): 776-785.
doi: 10.1055/s-0032-1312646
28 BEGUMN, SHENW, MANGANIELLOV. Role of PDE3A in regulation of cell cycle progression in mouse vascular smooth muscle cells and oocytes: implications in cardiovascular diseases and infertility[J]Curr Opin Pharmacol, 2011, 11( 6): 725-729.
doi: 10.1016/j.coph.2011.10.006
29 AZEVEDOM F, FAUCZF R, BIMPAKIE, et al.Clinical and molecular genetics of the phosphodiesterases (PDEs)[J]Endocrine Rev, 2014, 35( 2): 195-233.
doi: 10.1210/er.2013-1053
30 ZHENGH, YANGH, GONGD, et al.Progress in the mechanism and clinical application of cilostazol[J]Curr Top Med Chem, 2020, 19( 31): 2919-2936.
doi: 10.2174/1568026619666191122123855
31 RIEDERF, SIEGMUNDB, BUNDSCHUHD S, et al.The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice[J/OL]PLoS One, 2013, 8( 2): e56867.
doi: 10.1371/journal.pone.0056867
32 KANGAWAY, YOSHIDAT, ABEH, et al.Anti-inflammatory effects of the selective phosphodiesterase 3 inhibitor, cilostazol, and antioxidants, enzymatically-modified isoquercitrin and α-lipoic acid, reduce dextran sulphate sodium-induced colorectal mucosal injury in mice[J]Exp Toxicologic Pathol, 2017, 69( 4): 179-186.
doi: 10.1016/j.etp.2016.12.004
33 ALAM, MOHAMMAD JAFARIR, DEHPOURA R. Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: thinking about new indications[J]Fundam Clin Pharmacol, 2021, 35( 2): 235-259.
doi: 10.1111/fcp.12633
34 KHOSHAKHLAGHP, BAHROLOLOUMI-SHAPOURABADIM, MOHAMMADIRADA, et al.Beneficial effect of phosphodiesterase-5 inhibitor in experimental inflammatory bowel disease; molecular evidence for involvement of oxidative stress[J]Toxicol Mech Methods, 2007, 17( 5): 281-288.
doi: 10.1080/15376510601003769
35 DINAA A L, WALAAY A, OLFATG S, et al.Evaluation of the colo-protective effects of tadalafil in an experimental model of ulcerative colitis in rats[J]Afr J Pharm Pharmacol, 2017, 11( 32): 385-393.
doi: 10.5897/AJPP2017.4820
36 KARAKOYUNB, USLUU, ERCANF, et al.The effect of phosphodiesterase-5 inhibition by sildenafil citrate on inflammation and apoptosis in rat experimental colitis[J]Life Sci, 2011, 89( 11-12): 402-407.
doi: 10.1016/j.lfs.2011.07.005
37 LIN S, WANG J, WANG L, et al. Phosphodiesterase-5 inhibition suppresses colonic inflammation-induced tumorigenesis via blocking the recruitment of MDSC[J]. Am J Cancer Res, 2017, 7(1): 41-52
38 ISERIS O, ERSOYY, ERCANF, et al.The effect of sildenafil, a phosphodiesterase-5 inhibitor, on acetic acid-induced colonic inflammation in the rat[J]J Gastroenterol Hepatol, 2009, 24( 6): 1142-1148.
doi: 10.1111/j.1440-1746.2009.05797.x
39 FAKHFOURIG, RAHIMIANR, HASHEMIS, et al.Sildenafil attenuates TNBS-induced colitis in rats: possible involvement of cGMP and KATP channels[J]Fundamental Clin Pharmacol, 2012, 26( 2): 190-193.
doi: 10.1111/j.1472-8206.2011.00928.x
40 MARGONISG A, CHRISTOLOUKASN, ANTONIOUE, et al.Effectiveness of sildenafil and U-74389G in a rat model of colitis[J]J Surg Res, 2015, 193( 2): 667-674.
doi: 10.1016/j.jss.2014.08.064
41 ISLAMB N, SHARMANS K, HOUY, et al.Sildenafil suppresses inflammation-driven colorectal cancer in mice[J]Cancer Prev Res, 2017, 10( 7): 377-388.
doi: 10.1158/1940-6207.CAPR-17-0015
42 BEAUGERIEL, ITZKOWITZS H. Cancers complicating inflammatory bowel disease[J]N Engl J Med, 2015, 372( 15): 1441-1452.
doi: 10.1056/NEJMra1403718
43 CASTROA, JEREZM J, GILC, et al.Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors[J]Med Res Rev, 2005, 25( 2): 229-244.
doi: 10.1002/med.20020
44 CHARNIGOR J, BEIDLERD, RYBIND, et al.PF ‐04447943, a phosphodiesterase 9A inhibitor, in stable sickle cell disease patients: a phase Ⅰb randomized, placebo‐controlled study[J]Clin Transl Sci, 2019, 12( 2): 180-188.
doi: 10.1111/cts.12604
45 SCHWAME M, NICHOLAST, CHEWR, et al.A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer’s disease[J]Curr Alzheimer Res, 2014, 11( 5): 413-421.
doi: 10.2174/1567205011666140505100858
46 PRICKAERTSJ, HECKMANP R A, BLOKLANDA. Investigational phosphodiesterase inhibitors in phase Ⅰ and phase Ⅱ clinical trials for Alzheimer’s disease[J]Expert Opin Investig Drugs, 2017, 26( 9): 1033-1048.
doi: 10.1080/13543784.2017.1364360
47 RANAM N, LUJ, XUEE, et al.PDE9 inhibitor PF-04447943 attenuates DSS-induced colitis by suppressing oxidative stress, inflammation, and regulating T-cell polarization[J]Front Pharmacol, 2021, 643215.
doi: 10.3389/fphar.2021.643215
48 GARCíAA M, BREAJ, MORALES-GARCíAJ A, et al.Modulation of camp-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors[J]J Med Chem, 2014, 57( 20): 8590-8607.
doi: 10.1021/jm501090m
[1] 马丽娟,吴爽,张凯,田梅,张宏. 大麻素1型受体正电子发射断层显像在神经精神疾病中的应用进展[J]. 浙江大学学报（医学版）, 2021, 50(5): 666-673.
[2] 宣自学,张轶雯,潘宗富,郑小卫,黄萍. 天然药物成分干预铁死亡抑制肿瘤的作用研究进展[J]. 浙江大学学报（医学版）, 2021, 50(5): 601-606.
[3] 曲文政,庄英粮,李学坤. 表观遗传修饰在神经退行性变性疾病中的作用研究进展[J]. 浙江大学学报（医学版）, 2021, 50(5): 642-650.
[4] 孙琦,曹蔚,罗建红. 含GluN3亚基的N-甲基-D-天冬氨酸受体及其在中枢神经系统的功能[J]. 浙江大学学报（医学版）, 2021, 50(5): 651-658.
[5] 唐玥,孔元原. 遗传性酪氨酸血症Ⅰ型及其筛查和诊治进展[J]. 浙江大学学报（医学版）, 2021, 50(4): 514-523.
[6] 刘飞,冯春月,毛建华,傅海东. 2019冠状病毒病疫苗接种相关新发及复发肾小球病研究进展[J]. 浙江大学学报（医学版）, 2021, 50(4): 524-528.
[7] 韩连书. 新生儿遗传病基因筛查技术及相关疾病[J]. 浙江大学学报（医学版）, 2021, 50(4): 429-435.
[8] 胡茫莎,韦树丽,周武源,王苹莉. 新生儿Fc受体基础研究和临床应用进展[J]. 浙江大学学报（医学版）, 2021, 50(4): 537-544.
[9] 胡靖依,王青青,刘杨. 蛋白酶体亚基对肝细胞癌发生发展的调控作用研究进展[J]. 浙江大学学报（医学版）, 2021, 50(3): 396-402.
[10] 葛瀛洲,刘欣梅,黄荷凤. 沉默信息调节因子家族参与病理妊娠的研究进展[J]. 浙江大学学报（医学版）, 2021, 50(3): 335-344.
[11] 王锦涛,黄蕾,魏丽丽,陈炜. 重复经颅磁刺激治疗阿尔茨海默病患者的疗效影响因素[J]. 浙江大学学报（医学版）, 2021, 50(3): 383-389.
[12] 庄文雯,杨咏琪,李洪亮,梁景岩. 动脉粥样硬化过程中核因子E2相关因子2对血管平滑肌细胞的调控作用[J]. 浙江大学学报（医学版）, 2021, 50(3): 390-395.
[13] 朱锋,项迎春,曾玲晖. 线粒体沉默信息调节因子家族在癫痫发生发展中的作用研究进展[J]. 浙江大学学报（医学版）, 2021, 50(3): 403-408.
[14] 旷文静,罗小波,王冏珂,曾昕. 梅–罗综合征患者的表征及其诊治[J]. 浙江大学学报（医学版）, 2021, 50(2): 148-154.
[15] 王晨宇,王英男,汪存艺,施洁珺,王慧明. 组织工程修复颞下颌关节的关键因素研究进展[J]. 浙江大学学报（医学版）, 2021, 50(2): 212-221.